(Q44011661)

28 November 2017

title

Luteal phase support using either Crinone 8% or Utrogest: results of a prospective, randomized study (English)

1 reference

28 November 2017

Ludwig M

1

1 reference

28 November 2017

Schwartz P

2

1 reference

28 November 2017

Babahan B

3

1 reference

28 November 2017

Katalinic A

4

1 reference

28 November 2017

Weiss JM

5

1 reference

28 November 2017

Felberbaum R

6

1 reference

28 November 2017

Al-Hasani S

7

1 reference

28 November 2017

Diedrich K

8

1 reference

28 November 2017

publication date

1 June 2002

1 reference

European Journal of Obstetrics Gynecology and Reproductive Biology

28 November 2017

published in

1 reference

28 November 2017

volume

103

1 reference

28 November 2017

issue

1

1 reference

28 November 2017

page(s)

48-52

1 reference

A prospective randomized trial of human chorionic gonadotrophin or dydrogesterone support following in-vitro fertilization and embryo transfer

28 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2802%2900010-6

7 January 2021

Luteal support after luteinizing hormone-releasing hormone agonist for in vitro fertilization: superiority of human chorionic gonadotropin over oral progesterone

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2802%2900010-6

7 January 2021

A prospective randomized comparison of intramuscular or intravaginal natural progesterone as a luteal phase and early pregnancy supplement

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2802%2900010-6

7 January 2021

Oral versus intramuscular progesterone for in vitro fertilization: a prospective randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2802%2900010-6

7 January 2021

Use of Crinone vaginal progesterone gel for luteal support in in vitro fertilization cycles

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2802%2900010-6

7 January 2021

Comparison of the pharmacokinetics of crinone 8% administered vaginally versus Prometrium administered orally in postmenopausal women(3).

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2802%2900010-6

7 January 2021

Effects of natural progesterone on the morphology of the endometrium in patients with primary ovarian failure

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2802%2900010-6

7 January 2021

Targeted drug delivery in gynaecology: the first uterine pass effect

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2802%2900010-6

7 January 2021

Transvaginal progesterone: evidence for a new functional 'portal system' flowing from the vagina to the uterus

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2802%2900010-6

7 January 2021

Uterine contractions at the time of embryo transfer alter pregnancy rates after in-vitro fertilization

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2802%2900010-6

7 January 2021

The cumulative embryo score: a predictive embryo scoring technique to select the optimal number of embryos to transfer in an in-vitro fertilization and embryo transfer programme

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2802%2900010-6

7 January 2021

Evaluation of an optimal luteal phase support protocol in IVF.

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2802%2900010-6

7 January 2021

Prospective, randomized study to evaluate the success rates using hCG, vaginal progesterone or a combination of both for luteal phase support

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2802%2900010-6

7 January 2021

Hormonal monitoring for in-vitro fertilization and related procedures

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2802%2900010-6

7 January 2021

Luteal phase support in in-vitro fertilization using gonadotrophin releasing hormone analogue before ovarian stimulation: a prospective randomized study of human chorionic gonadotrophin versus intramuscular progesterone

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2802%2900010-6

7 January 2021

Prospective randomized comparison of human chorionic gonadotropin versus intramuscular progesterone for luteal-phase support in assisted reproduction.

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2802%2900010-6

7 January 2021

Progesterone alone versus progesterone combined with HCG as luteal support in GnRHa/HMG induced IVF cycles: a randomized clinical trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2802%2900010-6

7 January 2021

The benefits of mid-luteal addition of human chorionic gonadotrophin in in-vitro fertilization using a down-regulation protocol and luteal support with progesterone

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2802%2900010-6

7 January 2021

The first uterine pass effect

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2802%2900010-6

7 January 2021

Experience with a novel vaginal progesterone preparation in a donor oocyte program

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2802%2900010-6

7 January 2021

Crinone 8% (90 mg) given once daily for progesterone replacement therapy in donor egg cycles

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2802%2900010-6

7 January 2021

Crinone 8% vaginal progesterone gel results in lower embryonic implantation efficiency after in vitro fertilization-embryo transfer

1 reference

https://api.crossref.org/works/10.1016%2FS0301-2115%2802%2900010-6

7 January 2021

10.1016/S0301-2115(02)00010-6

Identifiers

DOI

1 reference

28 November 2017

1 reference